Details for Patent: 6,034,098

Title:	Inhibitors of microsomal triglyceride transfer protein and method
Abstract:	Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein R.sup.1 to R.sup.7, Q, X and Y are as defined herein.
Inventor(s):	Biller; Scott A. (Hopewell, NJ), Dickson; John K. (Eastampton, NJ), Lawrence; R. Michael (Yardley, PA), Magnin; David R. (Hamilton, NJ), Poss; Michael A. (Lawrenceville, NJ), Sulsky; Richard B. (Franklin Park, NJ), Tino; Joseph A. (Lawrenceville, NJ), Lawson; John E. (Wallingford, CT), Holava; Henry M. (Meriden, CT), Partyka; Richard A. (Neshanic, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:	Jul 21, 1997
Application Number:	08/898,304
Claims:	1. A compound which has the structure ##STR641## R.sup.8, R.sup.9 and R.sup.10 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl; R.sup.1 is a fluorenyl-type group of the structure ##STR642## R.sup.1 is an indenyl-type group of the structure ##STR643## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O,S, ##STR644## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, theteroaryl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR645## Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-heteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkyl-carbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.2, R.sup.3, R.sup.4 are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; ##STR646## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and a pharmaceutically acceptable salt thereof. 2. The compound as defined in claim 1 having the formula ##STR647## and a pharmaceutically acceptable salt thereof. 3. The compound as defined in claim 1 wherein R.sup.1 is ##STR648## 4. The compound as defined in claim 3, wherein R.sup.1 is Z is a bond, O or S; R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are each H or one of R.sup.15 and R.sup.16 and one of R.sup.13 and R.sup.14 are halogen; Z.sup.1 is a bond or C.dbd.O; R.sup.11 is alkylene or alkenylene; R.sup.12 -Z.sup.2 is ##STR649## R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl. 5. The compound as defined in claim 1 having the structure ##STR650## Z is O, S or a bond; R.sup.13 and R15 are independently H or F; Z.sup.1 is a bond; R.sup.11 is alkylene; R.sup.12 -Z.sup.2 is ##STR651## and R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl. 6. The compound as defined in claim 5 wherein R.sup.11 is --(CH.sub.2).sub.4 --, Z.sup.1 is a bond, and R.sup.12 -Z.sup.2 is ##STR652## 7. The compound as defined in claim 5 having the structure where R.sup.13 and R.sup.15 are independently H or F, and R.sup.12 is trifluoromethylalkyl or alkyl. 8. The compound as defined in claim 1 having the structure ##STR653## where R.sup.12 is alkyl, and R.sup.13 and R.sup.15 are independently H or F. 9. The compound as defined in claim 1 wherein R.sup.1 is an indenyl-type group of the structure ##STR654## 10. 10. The compound as defined in claim 1 wherein R.sup.1 is a group of the structure 11. The compound as defined in claim 1 having the structure Z is O, S or a bond; R.sup.13 and R.sup.15 are independently H or F; Z.sup.1 is a bond; R.sup.11 is alkylene; R.sup.12 -Z.sup.2 is ##STR655## and R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl. 12. The compound as defined in claim 1 which is: 2-[1-[2-(9H-fluoren-9-yl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-isoindol-1-on e; 2,3-dihydro-2-[1-[2-[9-(2-propylenyl)-9H-fluoren-9-yl]ethyl]-4-piperidinyl] -1H-isoindol-1-one; (Z)-2-[1-[4-(9H-fluoren-9-yl)-2-butenyl]-4-piperidinyl]-2,3-dihydro-1H-isoi ndol-1-one; (Z)-2,3-dihydro-2-[1-[4-[9-(2-propenyl)-9H-fluoren-9-yl]-2-butenyl]-4-piper idinyl]-1H-isoindol-1-one; and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above. 13. The compound as defined in claim 1 which is ##STR656## 9-[3-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1 -piperidinyl]propyl]-N-propyl-9H-fluorene-9-carboxamide; 2,3-dihydro-2-[1-[4-oxo-4-(9-propyl-9H-fluoren-9-yl)butyl]-4-piperidinyl]-1 H-isoindol-1-one or its monohydrochloride salt; (E)-9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- 2,7-difluoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-2,7-diflu oro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; (Z)-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- N-propyl-9H-fluorene-9-carboxamide; 2,3-dihydro-2-[1-[2-oxo-2-(9-propyl-9H-fluoren-9-yl)ethyl]-4-piperidinyl]-1 H-isoindol-1-one; (E)-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- N-propyl-9H-fluorene-9-carboxamide; 9-[3-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]propyl]-N-propyl -9H-fluorene-9-carboxamide; ##STR657## N-[2-[4-(1,3-dihydro-1-oxo -2H-isoindol-2-yl)-1-piperidinyl]-ethyl]-9-propyl-9H-fluorene-9-carboxamide 9-[5-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]pentyl]-N-propyl -9H-fluorene-9-carboxamide; 9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[2-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-ethyl]-N-propyl -9H-fluorene-9-carboxamide; N-ethyl-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-9 H-fluorene-9-carboxamide; 9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-2,2,2-t rifluoroethyl-9H-xanthene-9-carboxamide; 9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-butyl]-N-propyl -9H-xanthene-9-carboxamide; 9-[4-[4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-pro pyl-9H-fluorene-9-carboxamide; 9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-propyl- 9H-indeno[2,1-b]pyridine-9-carboxamide; 2,3-dihydro-2-[1-[4-hydroxy-4-(9-propyl-9H-fluoren-9-yl)butyl]-4-piperidiny l]-1H-isoindol-1-one; 2. 3-dihydro-2-[1-[3-[(9-propyl-9H-fluoren-9-yl)thio]propyl]-4-piperidinyl] -1H-isoindol-1-one; 2,3-dihydro-2-[1-[3-[(9-propyl-9H-fluoren-9-yl)sulfonyl]propyl]-4-piperidin yl]-1H-isoindol-1-one; and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above. 14. The compound as defined in claim 1 which is 2,3-dihydro-1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]buty l]-N-propyl-1H-indene-1-carboxamide; trans-2,3-dihydro-1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidiny l]butyl]-2-phenyl-N-propyl-1H-indene-1-carboxamide; 1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-2-phenyl- N-propyl-1H-indene-1-carboxamide; 2-1-[4-[9-(butylsulfonyl)-9H-fluoren-9-yl]butyl]-4-piperidinyl]-2,3-dihydro -1H-isoindol-1-one; 9-[4-[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)]-1-piperidinyl]butyl]-2,7 -difluoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 2,3-dihydro-2-[1-[4-[9-(1-oxopentyl)-9H-fluoren-9-yl]butyl]-4-piperidinyl]- 1H-isoindol-1-one; 9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[4-(4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,3, 3,4,4,4-heptafluorobutyl)-9H-fluorene-9-carboxamide; 1-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-2-methyl- N-(2,2,2-trifluoroethyl)-1H-indene-1-carboxamide; 9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,3, 3,3-pentafluoro-propyl)-9H-fluorene-9-carboxamide; 1-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-1H-indene-1-carboxamide; and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above. 15. A compound which has the structure ##STR658## R.sup.8, R.sup.9 and R.sup.10 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl; R.sup.1 is a fluorenyl-type group of the structure ##STR659## R.sup.1 is an indenyl-type group of the structure ##STR660## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR661## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, arylalkyl, arylalkenyl, cycloalkyl, trihaloalkyl, trihaloalkylalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR662## and Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, carboxy, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.2, R.sup.3, R.sup.4 are independently hydrogen, halo, alkyl, haloalkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; ##STR663## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or a pharmaceutically acceptable salt thereof. 16. A method for preventing, inhibiting or treating atherosclerosis; pancreatitis secondary to hypertriglyceridemia; or hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity secondary to malabsorption of dietary fat in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1. 17. A method of lowering serum lipid levels, cholesterol and/or triglycerides, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.